FTC Asks Novartis To Shed Drug For Alcon Deal

Law360, New York (August 16, 2010, 4:53 PM EDT) -- The Federal Trade Commission said Monday that Novartis AG would be required to sell injectable eye drug Miochol-E to Bausch & Lomb Inc. to quell fears that the drugmaker's proposed acquisition of a majority stake in Alcon Laboratories Inc. would quash competition in the eye care market.

FTC commissioners voted 4-0-1, with Commissioner William E. Kovacic recused, to approve the complaint and proposed settlement order, which will be open for public comment until Sept. 16, according to FTC officials.

According to the FTC's complaint, the proposed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.